De-escalation of neoadjuvant chemotherapy in resectable oral squamous cell carcinoma: results of a comparative analysis of DC and DCF modes

Introduction. The three-drug regimen consisting of docetaxel, cisplatin, and 5-fluorouracil (DCF) has traditionally been regarded as one of the most active neoadjuvant chemotherapy regimens for locally advanced head and neck squamous cell carcinoma. However, its use is associated with a high incidence of treatment-related adverse events. Therefore, the two-drug regimen of docetaxel plus cisplatin (DC) may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma. Aim. To compare the short-term antitumor efficacy and toxicity profile of two- versus three-drug taxane-platinum neoadjuvant chemotherapy regimens in patients with resectable locally advanced oral squamous cell carcinoma. Materials and methods. This single-center retrospective cohort study included 45 patients with resectable locally advanced oral squamous cell carcinoma who received neoadjuvant chemotherapy followed by surgery between 2020 and 2026. Twenty-eight patients (62.2 %) received the DCF regimen, whereas 17 (37.8 %) received the DC regimen. Radiological response was assessed according to Response Evaluation Criteria in Solid Tumors 1.1. Pathologic response was classified as pathologic complete response, major pathologic response, or unfavorable pathologic response. Treatment-related toxicity was evaluated using the Common Terminology Criteria for Adverse Events, version 5.0. All patients received primary prophylaxis against chemotherapy-induced neutropenia with epegfilgrastim. Results. The objective response rate was 58.8 % in the DC group and 53.6 % in the DCF group (p = 0.767), whereas disease control rates were 100 and 89.3 %, respectively (p = 0.279). Tumor downstaging (reduction in T category) was observed in 64.7 and 64.3 % of patients, respectively (p = 1.000), while nodal downstaging (reduction in N category) occurred in 17.6 and 21.4 %, respectively (p = 1.000). The complete pathologic response rate was 11.8 % in the DC group and 10.7 % in the DCF group (p = 0.990), whereas the favorable pathologic response rate (complete pathologic response + major pathologic response) was 41.2 and 39.3 %, respectively (p = 1.000). R0 resection was achieved in all patients. Grade 3 adverse events occurred more frequently in the DCF group than in the DC group (53.6 % vs 17.6 %, p = 0.028), primarily because of a higher incidence of grade 3 non-hematological toxicity (42.9 % vs 5.9 %, p = 0.015). No cases of febrile neutropenia were observed. Conclusion. Among patients with resectable locally advanced oral squamous cell carcinoma, no statistically significant differences were observed between the DC and DCF regimens regarding objective response, disease control, tumor and nodal downstaging, pathologic response, or R0 resection rates. The DC regimen was associated with a significantly lower incidence of grade 3 adverse events, primarily owing to reduced non-hematological toxicity. These findings suggest that DC may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma.

Authors

Institutions

Publication Details

Journal
Head and neck tumors (HNT)
Published
2026-11-20
DOI
https://doi.org/10.17650/2222-1468-2026-16-3-42-51
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

De-escalation of neoadjuvant chemotherapy in resectable oral squamous cell carcinoma: results of a comparative analysis of DC and DCF modes

Sergey Vladimirovich Vtorushin, Константин Викторович Меньшиков, Шамиль Исмагилович Мусин, Шарифгалиев Ильдар Асхадуллович et al.
Head and neck tumors (HNT)
Head and Neck Cancer Studies
article

De-escalation of neoadjuvant chemotherapy in resectable oral squamous cell carcinoma: results of a comparative analysis of DC and DCF modes

Sergey Vladimirovich Vtorushin, Константин Викторович Меньшиков, Шамиль Исмагилович Мусин, Шарифгалиев Ильдар Асхадуллович, А. В. Султанбаев, T. R. Baymuratov, Е. Л. Чойнзонов, Н. А. Шарафутдинова, M. R. Shafikova, E. V. Tiulcov
article en

Abstract

Introduction. The three-drug regimen consisting of docetaxel, cisplatin, and 5-fluorouracil (DCF) has traditionally been regarded as one of the most active neoadjuvant chemotherapy regimens for locally advanced head and neck squamous cell carcinoma. However, its use is associated with a high incidence of treatment-related adverse events. Therefore, the two-drug regimen of docetaxel plus cisplatin (DC) may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma. Aim. To compare the short-term antitumor efficacy and toxicity profile of two- versus three-drug taxane-platinum neoadjuvant chemotherapy regimens in patients with resectable locally advanced oral squamous cell carcinoma. Materials and methods. This single-center retrospective cohort study included 45 patients with resectable locally advanced oral squamous cell carcinoma who received neoadjuvant chemotherapy followed by surgery between 2020 and 2026. Twenty-eight patients (62.2 %) received the DCF regimen, whereas 17 (37.8 %) received the DC regimen. Radiological response was assessed according to Response Evaluation Criteria in Solid Tumors 1.1. Pathologic response was classified as pathologic complete response, major pathologic response, or unfavorable pathologic response. Treatment-related toxicity was evaluated using the Common Terminology Criteria for Adverse Events, version 5.0. All patients received primary prophylaxis against chemotherapy-induced neutropenia with epegfilgrastim. Results. The objective response rate was 58.8 % in the DC group and 53.6 % in the DCF group (p = 0.767), whereas disease control rates were 100 and 89.3 %, respectively (p = 0.279). Tumor downstaging (reduction in T category) was observed in 64.7 and 64.3 % of patients, respectively (p = 1.000), while nodal downstaging (reduction in N category) occurred in 17.6 and 21.4 %, respectively (p = 1.000). The complete pathologic response rate was 11.8 % in the DC group and 10.7 % in the DCF group (p = 0.990), whereas the favorable pathologic response rate (complete pathologic response + major pathologic response) was 41.2 and 39.3 %, respectively (p = 1.000). R0 resection was achieved in all patients. Grade 3 adverse events occurred more frequently in the DCF group than in the DC group (53.6 % vs 17.6 %, p = 0.028), primarily because of a higher incidence of grade 3 non-hematological toxicity (42.9 % vs 5.9 %, p = 0.015). No cases of febrile neutropenia were observed. Conclusion. Among patients with resectable locally advanced oral squamous cell carcinoma, no statistically significant differences were observed between the DC and DCF regimens regarding objective response, disease control, tumor and nodal downstaging, pathologic response, or R0 resection rates. The DC regimen was associated with a significantly lower incidence of grade 3 adverse events, primarily owing to reduced non-hematological toxicity. These findings suggest that DC may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma.

Head and neck tumors (HNT)Vol. 16(3)
Russian Academy of Sciences (RU), Siberian State Medical University (RU), Ministry of Health of the Russian Federation (RU), Tomsk National Research Medical Center (RU), Bashkir State Medical University (RU), Republican Oncological Clinical Dispensary (RU)
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon